These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19372978)

  • 1. Pediatric clinical pharmacology and its implications for antiretroviral drug development.
    King J; Acosta E
    Curr Opin HIV AIDS; 2008 May; 3(3):272-6. PubMed ID: 19372978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy in developing countries: pharmacologic considerations.
    Lamorde M; Byakika-Kibwika P; Merry C
    Curr Opin HIV AIDS; 2008 May; 3(3):252-7. PubMed ID: 19372975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latent HIV-1 reservoirs in children: considerations for therapy.
    Persaud D
    Curr Opin HIV AIDS; 2006 Mar; 1(2):174-8. PubMed ID: 19372804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric HIV infection: the state of antiretroviral therapy.
    McKellar MS; Callens SF; Colebunders R
    Expert Rev Anti Infect Ther; 2008 Apr; 6(2):167-80. PubMed ID: 18380599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric HIV: new opportunities to treat children.
    Van der Linden D; Callens S; Brichard B; Colebunders R
    Expert Opin Pharmacother; 2009 Aug; 10(11):1783-91. PubMed ID: 19558340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of HIV protease inhibitors in pregnancy.
    van der Lugt J; Colbers A; Burger D
    Curr Opin HIV AIDS; 2008 Nov; 3(6):620-6. PubMed ID: 19373033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can we simplify antiretroviral therapy in children?
    Sohn AH; Ananworanich J
    Curr Opin HIV AIDS; 2007 Sep; 2(5):426-30. PubMed ID: 19372922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune reconstitution disease: recent developments and implications for antiretroviral treatment in resource-limited settings.
    Lawn SD; French MA
    Curr Opin HIV AIDS; 2007 Jul; 2(4):339-45. PubMed ID: 19372909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A regulatory perspective on the role of drug interactions in antiretroviral drug development.
    Struble KA; Reynolds KS
    Curr Opin HIV AIDS; 2008 May; 3(3):325-9. PubMed ID: 19372986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.
    Kiser JJ
    Curr Opin HIV AIDS; 2008 May; 3(3):330-41. PubMed ID: 19372987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of antiretroviral drug interaction studies.
    Kakuda TN; Schöller-Gyüre M
    Curr Opin HIV AIDS; 2008 May; 3(3):313-8. PubMed ID: 19372984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies.
    Mallon PW
    Curr Opin HIV AIDS; 2007 Jul; 2(4):282-92. PubMed ID: 19372900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early treatment of HIV: implications for resource-limited settings.
    Hobbs CV; Essajee SM
    Curr Opin HIV AIDS; 2009 May; 4(3):222-31. PubMed ID: 19532054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early antiretroviral therapy mortality in resource-limited settings: what can we do about it?
    Bekker LG; Egger M; Wood R
    Curr Opin HIV AIDS; 2007 Jul; 2(4):346-51. PubMed ID: 19372910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance and viral subtypes: how important are the differences and why do they occur?
    Brenner BG
    Curr Opin HIV AIDS; 2007 Mar; 2(2):94-102. PubMed ID: 19372873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management of drug interaction with antiretroviral agents.
    Pau AK
    Curr Opin HIV AIDS; 2008 May; 3(3):319-24. PubMed ID: 19372985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of the principles of developmental pharmacology to the study of environmental toxicants.
    McCarver DG
    Pediatrics; 2004 Apr; 113(4 Suppl):969-72. PubMed ID: 15060189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of antiretroviral drug toxicity.
    Feeney E; Muldoon E; Powderly WG
    Curr Opin HIV AIDS; 2006 Sep; 1(5):430-6. PubMed ID: 19372843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs.
    Anderson PL
    Curr Opin HIV AIDS; 2008 May; 3(3):258-65. PubMed ID: 19372976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.
    MacDonald L; Murty M; Foster BC
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):563-78. PubMed ID: 19442034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.